Phase 1 open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-2130 administered as daily IV infusions for 5 days, in patients with refractory cancer.
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2009
At a glance
- Drugs MPC 2130 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 27 Oct 2009 Actual number of patients (8) added as reported by ClinicalTrials.gov record.
- 27 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 May 2007 New trial record.